Ligation of OX40 (TNFRSF4, CD134) on the effector T cell surface by OX40 agonists causes the receptor to oligomerize (cluster) and stimulates intracellular signaling, which enhances anti-tumor immunity leading to therapeutic effects in cancers [33,34,35]. Here, TNFRSF4 is linked to cancer.